A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia

Mark Schiffman, Ana Cecilia Rodriguez, Zigui Chen, Sholom Wacholder, Rolando Herrero, Allan Hildesheim, Rob Desalle, Brian Befano, Kai Yu, Mahboobeh Safaeian, Mark E. Sherman, Jorge Morales, Diego Guillen, Mario Alfaro, Martha Hutchinson, Diane Solomon, Philip E. Castle, Robert D. Burk

Research output: Contribution to journalArticle

161 Citations (Scopus)

Abstract

Human papillomavirus (HPV) types differ profoundly in cervical carcinogenicity. For the most carcinogenic type HPV16, variant lineages representing further evolutionary divergence also differ in cancer risk. Variants of the remaining 10 to 15 carcinogenic HPV types have not been well studied. In the first prospective, populationbased study of HPV variants, we explored whether, on average, the oldest evolutionary branches within each carcinogenic type predicted different risks of >2-year viral persistence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)]. We examined the natural history of HPV variants in the 7-year, 10,049-woman Guanacaste Cohort Study, using a nested case-control design. Infections were assigned to a variant lineage determined by phylogenetic parsimony methods based on URR/E6 sequences. We used the Fisher's combination test to evaluate significance of the risk associations, cumulating evidence across types. Globally, for HPV types including HPV16, the P value was 0.01 for persistence and 0.07 for CIN3+. Excluding HPV16, the P values were 0.04 and 0.37, respectively. For HPV16, non-European viral variants were significantly more likely than European variants to cause persistence [odds ratio (OR), 2.6; P = 0.01] and CIN3+ (OR, 2.4; P = 0.004). HPV35 and HPV51 variant lineages also predicted CIN3+. HPV variants generally differ in risk of persistence. For some HPV types, especially HPV16, variant lineages differ in risk of CIN3+. The findings indicate that continued evolution of HPV types has led to even finer genetic discrimination linked to HPV natural history and cervical cancer risk. Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity.

Original languageEnglish (US)
Pages (from-to)3159-3169
Number of pages11
JournalCancer Research
Volume70
Issue number8
DOIs
StatePublished - Apr 15 2010

Fingerprint

Prospective Studies
Cervical Intraepithelial Neoplasia
Population
Neoplasms
Natural History
Odds Ratio
Uterine Cervical Neoplasms
Cohort Studies
Infection

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. / Schiffman, Mark; Rodriguez, Ana Cecilia; Chen, Zigui; Wacholder, Sholom; Herrero, Rolando; Hildesheim, Allan; Desalle, Rob; Befano, Brian; Yu, Kai; Safaeian, Mahboobeh; Sherman, Mark E.; Morales, Jorge; Guillen, Diego; Alfaro, Mario; Hutchinson, Martha; Solomon, Diane; Castle, Philip E.; Burk, Robert D.

In: Cancer Research, Vol. 70, No. 8, 15.04.2010, p. 3159-3169.

Research output: Contribution to journalArticle

Schiffman, M, Rodriguez, AC, Chen, Z, Wacholder, S, Herrero, R, Hildesheim, A, Desalle, R, Befano, B, Yu, K, Safaeian, M, Sherman, ME, Morales, J, Guillen, D, Alfaro, M, Hutchinson, M, Solomon, D, Castle, PE & Burk, RD 2010, 'A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia', Cancer Research, vol. 70, no. 8, pp. 3159-3169. https://doi.org/10.1158/0008-5472.CAN-09-4179
Schiffman, Mark ; Rodriguez, Ana Cecilia ; Chen, Zigui ; Wacholder, Sholom ; Herrero, Rolando ; Hildesheim, Allan ; Desalle, Rob ; Befano, Brian ; Yu, Kai ; Safaeian, Mahboobeh ; Sherman, Mark E. ; Morales, Jorge ; Guillen, Diego ; Alfaro, Mario ; Hutchinson, Martha ; Solomon, Diane ; Castle, Philip E. ; Burk, Robert D. / A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. In: Cancer Research. 2010 ; Vol. 70, No. 8. pp. 3159-3169.
@article{30fa1a373f3349d29b770e13b28a520c,
title = "A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia",
abstract = "Human papillomavirus (HPV) types differ profoundly in cervical carcinogenicity. For the most carcinogenic type HPV16, variant lineages representing further evolutionary divergence also differ in cancer risk. Variants of the remaining 10 to 15 carcinogenic HPV types have not been well studied. In the first prospective, populationbased study of HPV variants, we explored whether, on average, the oldest evolutionary branches within each carcinogenic type predicted different risks of >2-year viral persistence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)]. We examined the natural history of HPV variants in the 7-year, 10,049-woman Guanacaste Cohort Study, using a nested case-control design. Infections were assigned to a variant lineage determined by phylogenetic parsimony methods based on URR/E6 sequences. We used the Fisher's combination test to evaluate significance of the risk associations, cumulating evidence across types. Globally, for HPV types including HPV16, the P value was 0.01 for persistence and 0.07 for CIN3+. Excluding HPV16, the P values were 0.04 and 0.37, respectively. For HPV16, non-European viral variants were significantly more likely than European variants to cause persistence [odds ratio (OR), 2.6; P = 0.01] and CIN3+ (OR, 2.4; P = 0.004). HPV35 and HPV51 variant lineages also predicted CIN3+. HPV variants generally differ in risk of persistence. For some HPV types, especially HPV16, variant lineages differ in risk of CIN3+. The findings indicate that continued evolution of HPV types has led to even finer genetic discrimination linked to HPV natural history and cervical cancer risk. Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity.",
author = "Mark Schiffman and Rodriguez, {Ana Cecilia} and Zigui Chen and Sholom Wacholder and Rolando Herrero and Allan Hildesheim and Rob Desalle and Brian Befano and Kai Yu and Mahboobeh Safaeian and Sherman, {Mark E.} and Jorge Morales and Diego Guillen and Mario Alfaro and Martha Hutchinson and Diane Solomon and Castle, {Philip E.} and Burk, {Robert D.}",
year = "2010",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-09-4179",
language = "English (US)",
volume = "70",
pages = "3159--3169",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia

AU - Schiffman, Mark

AU - Rodriguez, Ana Cecilia

AU - Chen, Zigui

AU - Wacholder, Sholom

AU - Herrero, Rolando

AU - Hildesheim, Allan

AU - Desalle, Rob

AU - Befano, Brian

AU - Yu, Kai

AU - Safaeian, Mahboobeh

AU - Sherman, Mark E.

AU - Morales, Jorge

AU - Guillen, Diego

AU - Alfaro, Mario

AU - Hutchinson, Martha

AU - Solomon, Diane

AU - Castle, Philip E.

AU - Burk, Robert D.

PY - 2010/4/15

Y1 - 2010/4/15

N2 - Human papillomavirus (HPV) types differ profoundly in cervical carcinogenicity. For the most carcinogenic type HPV16, variant lineages representing further evolutionary divergence also differ in cancer risk. Variants of the remaining 10 to 15 carcinogenic HPV types have not been well studied. In the first prospective, populationbased study of HPV variants, we explored whether, on average, the oldest evolutionary branches within each carcinogenic type predicted different risks of >2-year viral persistence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)]. We examined the natural history of HPV variants in the 7-year, 10,049-woman Guanacaste Cohort Study, using a nested case-control design. Infections were assigned to a variant lineage determined by phylogenetic parsimony methods based on URR/E6 sequences. We used the Fisher's combination test to evaluate significance of the risk associations, cumulating evidence across types. Globally, for HPV types including HPV16, the P value was 0.01 for persistence and 0.07 for CIN3+. Excluding HPV16, the P values were 0.04 and 0.37, respectively. For HPV16, non-European viral variants were significantly more likely than European variants to cause persistence [odds ratio (OR), 2.6; P = 0.01] and CIN3+ (OR, 2.4; P = 0.004). HPV35 and HPV51 variant lineages also predicted CIN3+. HPV variants generally differ in risk of persistence. For some HPV types, especially HPV16, variant lineages differ in risk of CIN3+. The findings indicate that continued evolution of HPV types has led to even finer genetic discrimination linked to HPV natural history and cervical cancer risk. Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity.

AB - Human papillomavirus (HPV) types differ profoundly in cervical carcinogenicity. For the most carcinogenic type HPV16, variant lineages representing further evolutionary divergence also differ in cancer risk. Variants of the remaining 10 to 15 carcinogenic HPV types have not been well studied. In the first prospective, populationbased study of HPV variants, we explored whether, on average, the oldest evolutionary branches within each carcinogenic type predicted different risks of >2-year viral persistence and/or precancer and cancer [cervical intraepithelial neoplasia grade 3+ (CIN3+)]. We examined the natural history of HPV variants in the 7-year, 10,049-woman Guanacaste Cohort Study, using a nested case-control design. Infections were assigned to a variant lineage determined by phylogenetic parsimony methods based on URR/E6 sequences. We used the Fisher's combination test to evaluate significance of the risk associations, cumulating evidence across types. Globally, for HPV types including HPV16, the P value was 0.01 for persistence and 0.07 for CIN3+. Excluding HPV16, the P values were 0.04 and 0.37, respectively. For HPV16, non-European viral variants were significantly more likely than European variants to cause persistence [odds ratio (OR), 2.6; P = 0.01] and CIN3+ (OR, 2.4; P = 0.004). HPV35 and HPV51 variant lineages also predicted CIN3+. HPV variants generally differ in risk of persistence. For some HPV types, especially HPV16, variant lineages differ in risk of CIN3+. The findings indicate that continued evolution of HPV types has led to even finer genetic discrimination linked to HPV natural history and cervical cancer risk. Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity.

UR - http://www.scopus.com/inward/record.url?scp=77951027069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951027069&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-4179

DO - 10.1158/0008-5472.CAN-09-4179

M3 - Article

C2 - 20354192

AN - SCOPUS:77951027069

VL - 70

SP - 3159

EP - 3169

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -